Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Dec 12;134(24):2218-2222.
doi: 10.1182/blood.2019002610.

Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy

Luzalba Sanoja-Flores  1   2   3   4   5 , Juan Flores-Montero  1   2   3   4   5 , Noemi Puig  1   4   5   6 , Teresa Contreras-Sanfeliciano  7 , Roberia Pontes  8 , Alba Corral-Mateos  1   2   3   4   5 , Omar García-Sánchez  1   4   5   6 , María Díez-Campelo  1   4   5   6 , Roberto José Pessoa de Magalhães  9 , Luis García-Martín  10 , José María Alonso-Alonso  11 , Aranzazú García-Mateo  12 , Carlos Aguilar-Franco  13 , Jorge Labrador  14 , Abelardo Barez-García  15 , Angelo Maiolino  9 , Bruno Paiva  4   16 , Jesús San Miguel  4   16 , Elaine Sobral da Costa  8 , Marcos González  1   4   5   6 , María Victoria Mateos  1   4   5   6 , Brian Durie  17 , Jacques J M van Dongen  18 , Alberto Orfao  1   2   3   4   5
Affiliations

Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy

Luzalba Sanoja-Flores et al. Blood. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: M.-V.M. declares honoraria for lectures and advisory boards from Janssen, Celgene, Amgen, Takeda, Abbvie, GSK, Adaptive, EDO-Mundipharma, and Pharmamar. The remaining authors declare no competing financial interests.

Figures

Figure 1.
Figure 1.
Prognostic impact of blood CTPC by NGF (vs BM MRD and sIF) on PFS of MM patients according to patient response to therapy. (A-B) Effect of PB CTPC, (D-E) BM MRD, (H) combination of both parameters, and (G) PB CTPC together with sIF status on PFS is displayed for (A, D, G) the entire MM cohort and (B, E, H) for sCR and CR patients, respectively. PFS curves of MM patients grouped according to (C) their sequential PB CTPC (−/− or +/− vs −/+ and +/+), (F) sIF status, or (I) a combination of both, are shown. Overall, CTPC− and MRD− was defined as the absence of TPC in PB or BM by NGF, respectively, with a limit of detection of <2 × 10−6. CR, complete response; NR, not reached; PB, peripheral blood.
See this image and copyright information in PMC

References

    1. Waldschmidt JM, Anand P, Knoechel B, Lohr JG. Comprehensive characterization of circulating and bone marrow-derived multiple myeloma cells at minimal residual disease. Semin Hematol. 2018;55(1):33-37. - PMC - PubMed
    1. Oberle A, Brandt A, Voigtlaender M, et al. . Monitoring multiple myeloma by next-generation sequencing of V(D)J rearrangements from circulating myeloma cells and cell-free myeloma DNA. Haematologica. 2017;102(6):1105-1111. - PMC - PubMed
    1. Sanoja-Flores L, Flores-Montero J, Garcés JJ, et al. ; EuroFlow consortium . Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC). Blood Cancer J. 2018;8(12):117. - PMC - PubMed
    1. Flores-Montero J, Sanoja-Flores L, Paiva B, et al. . Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 2017;31(10):2094-2103. - PMC - PubMed
    1. Bossuyt X, Bogaerts A, Schiettekatte G, Blanckaert N. Serum protein electrophoresis and immunofixation by a semiautomated electrophoresis system. Clin Chem. 1998;44(5):944-949. - PubMed

Publication types

MeSH terms